Skip to main content

Table 1 Clinical characteristics of the enrolled patients in the training group and the external validation group

From: Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study

 

Training group (n = 60)

Validation group (n = 32)

p value

Gender

Male

49

24

0.993

Female

11

8

 

Age (years)

60.60 ± 9.33

62.50 ± 5.86

0.340

Serum CA125 (Elevated)

6

1

0.300

Serum CA199 (Elevated)

8

5

0.241

Serum CEA (Elevated)

18

9

0.112

Serum albumin (Reduced)

29

1

0.315

Borrmann typing

I–II

32

10

0.010*

III–IV

28

22

 

Tumor thickness (cm)

   
 

18.19 ± 5.75

15.39 ± 5.14

0.036*

Degree of differentiation

Low

25

20

0.087

Middle-high

35

12

 

T-staging before NAC

4

31

21

0.122

2–3

29

11

 

N-staging before NAC

0–1

38

17

0.578

2–3

22

15

 

TRG

0

19

4

0.218

1

12

10

 

2

15

9

 

3

14

9

 
  1. NAC neoadjuvant chemotherapy, TRG tumor regression grade, CA carbohydrate antigen, CA199 (normal range 0.01–37 U/mL), CA125 (normal range 0.01–35 U/mL), CEA carcinoembryonic antigen (normal range 0–5 ng/mL)
  2. *Statistically significant level: p < 0.05